Patient info Open main menu

ORFADIN 2 MG HARD CAPSULES - patient leaflet, side effects, dosage

Contains active substance :

ATC code:

Dostupné balení:

Patient leaflet - ORFADIN 2 MG HARD CAPSULES

What Is In this leaflet

  • 1. What Otfadin is and what it is used for

  • 2. What you need to know before you take Otfadin

  • 3. How to take Otfadin

  • 4. Possible side effects

  • 5. How to store Otfadin

  • 6. Contents of the packand other information

1. what orfadin is and what it is used for

Orfadin contains the active substance nitisinone. Otfadin is used to treat:

  • – a rate disease called hereditary tyrosinemia type 1 in adults, adolescents and children (in any age range)

  • – a rate disease called alkaptonuria (AKU) in adults.

In these diseases your body is unable to completely breakdown the amino acid tyrosine (amino acids ate building blocks of out proteins), forming harmful substances.These substances ate accumulated in your body. Otfadin blocks the breakdown of tyrosine and the harmful substances ate not formed.

for the treatment of hereditary tyrosinemia type 1, you must follow a special diet while you ate taking this medicine, because tyrosine will remain in your body.This special diet is based on low tyrosine and phenylalanine (another amino acid) content.

for the treatment of AKU, your doctor may advise you to follow a special diet.

2. what you need to know before you take orfadin- if you ate allergic to nitisinone or any of the other ingredients of this medicine (listed in section 6).

Do not breast-feed while taking this medicine, see section „Pregnancy and breast-feeding“.

Warnings and precautions

Talkto your doctor or pharmacist before taking Otfadin.

  • – Your eyes will be checked by an ophthalmologist before and regularly during nitisinone treatment. If you get ted eyes or any other signs of effects on the eyes, contact your doctor immediately for an eye examination. Eye problems could be a sign of inadeguate dietary control (see section 4).

During the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adeguate and to make sure that there ate no possible side effects causing blood disorders.

If you receive Orfadin for treatment of hereditary tyrosinemia type 1, your liver will be checked at tegular intervals because the disease affects the liver.

follow-up by your doctor should be performed every 6 months. If you experience any side effects, shorter intervals ate recommended.

Other medicines and Orfadin

Tell your doctor or pharmacist if you ate taking, have recently taken or might take any other medicines.

Orfadin may interfere with the effect of other medicines, such as:

  • – Medicines for epilepsy (such as phenytoin)

  • – Medicines against blood clotting (such as warfarin).

Orfadin with food

If you start treatment by taking it with food, it is recommended that you catty on taking it with food throughout your course of treatment.

Pregnancy and breast-feeding

The safety of this medicine has not been studied in pregnant and breastfeeding wo­men.

Please contact your doctor if you plan to become pregnant. If you become

26

pregnant you should contact your doctor immediately.

Do not breast-feed while taking this medicine, see section „Do not take Orfadin“.

Driving and using machines

This medicine has minor influence on the ability to drive and use machines. However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4 „Possible side effects“).

3. how to take orfadin

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you ate not sure.

for hereditary tyrosinemia type 1, treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease.

for hereditary tyrosinemia type 1, the recommended total daily dose is

  • 1 mg/kg body weight administered orally. Your doctor will adjust the dose individually.

It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight <20 kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.

for AKU, the recommended dose is 10 mg once daily.

If you have problems with swallowing the capsules, you may open the capsule and mix the powder with a small amount of water or formula diet just before you take it.

If you take more Orfadin than you should

If you have taken more of this medicine than you should, contact your doctor or pharmacist as soon as possible.

If you forget to take Orfadin

Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, contact your doctor or pharmacist.

If you stop taking Orfadin

If you have the impression that the medicine is not working properly, talk to your doctor. Do not change the dose or stop the treatment without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you notice any side effects relating to the eyes, talk to your doctor immediately to have an eye examination. Treatment with nitisinone leads to higher levels of tyrosine in the blood which can cause eye related symptoms. In patients with hereditary tyrosinemia type 1, commonly reported eye related side effects (may affect more than 1 in 100 people) caused by higher tyrosine levels are inflammation in the eye (conjunctivitis), opacity and inflammation in the cornea (keratitis), sensitivity to light (photophobia) and eye pain. Inflammation of the eyelid (blepharitis) is an uncommon side effect (may affect up to 1 in 100 people).

In AKU patients, eye irritation (keratopathy) and eye pain are very commonly reported side effects (may affect more than 1 in 10 people).

Other side effects reported in patients with hereditary tyrosinemia type 1 are listed below:

Other common side effects

  • – reduced number of platelets (thrombocytopenia) and white blood cells (leukopenia), shortage of certain white blood cells (granulocytopenia).

Other uncommon side effects

  • – increased number of white blood cells (leucocytosis),

  • – itching (pruritus), skin inflammation (exfoliative dermatitis), rash.

Other side effects reported in patients with AKU are listed below:

Other common side effects

  • – bronchitis

  • – pneumonia

  • – itching (pruritus), rash.

5. how to store orfadin

Keep this medicine out of the sight and teach of children.

Do not use this medicine after the expiry date which is stated on the bottle and the carton after"EXP"

The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

The medicine can be stored for a single period of 2 months (for 2 mg capsules) or 3 months (for 5 mg, 10 mg and 20 mg capsules) at a temperature not above 25°C, after which it must be discarded.

Do not forget to mark the date on the bottle, when removed from the refrigerator.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throwaway medicines you no longer use.These measures will help to protect the environment.

6. contents of the pack and other informationthe active substance is nitisinone.

Orfadin 2 mg: Each capsule contains 2 mg nitisinone.

Orfadin 5 mg: Each capsule contains 5 mg nitisinone.

Orfadin Wmg: Each capsule contains 10 mg nitisinone.

Orfadin 20mg: Each capsule contains 20 mg nitisinone.

The other ingredients ate

Capsule content: starch, pregelatinised (maize).

Capsule shell: gelatine, titanium dioxide (E171).

Printing ink: iron oxide (E172), shellac, propylene glycol, ammonium hydroxide.

What Orfadin looks like and contents of the pack

The hard capsules ate white, opague, imprinted with „NTBC“ and the strength „2 mg“, „5 mg“, „10 mg“ or „20 mg“, in black. The capsule contains a white to off-white powder.

The capsules ate packaged in plastic bottles with tamper-proof closures. Each bottle contains 60 capsules.

Marketing Authorisation Holder

Swedish Orphan Biovitrum International AB

SE-112 76 Stockholm

Sweden

Manufacturer

Apotek Produktion & Laboratorier AB

Prismavagen 2

SE-14175 Kungens Kurva

Sweden

This leaflet was last revised in 10/2020

Detailed information on this medicine is available on the European Medicines Agency web site: ate also links to other websites about rate diseases and treatments.